| European Case Law Identifier: | ECLI:EP:BA:2012:T099009.20120703 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 03 July 2012 | ||||||||
| Case number: | T 0990/09 | ||||||||
| Application number: | 00969319.3 | ||||||||
| IPC class: | C12N 5/00 C12N 5/06 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Medium for the protein-free and serum-free cultivation of cells | ||||||||
| Applicant name: | Baxter Aktiengesellschaft | ||||||||
| Opponent name: | Merck Serono SA Maxygen Inc. Sigma-Aldrich Co. Kerry Ingredients (UK) Limited Novo Nordisk A/S F.Hoffmann-La Roche AG Novartis AG Campina Nederland Holding B.V. |
||||||||
| Board: | 3.3.08 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Admission of the main request and auxiliary request I filed at the oral proceedings (yes) Auxiliary request I: added matter (no) Novelty (yes) Remittal (yes) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t090990eu1.html
Date retrieved: 17 May 2021